Estimates of bladder cancer burden attributable to high fasting plasma glucose: Findings of the Global Burden of Disease Study 2019
Open Access
- 23 June 2023
- journal article
- research article
- Published by Wiley in Cancer Medicine
- Vol. 12 (15) , 16469-16481
Abstract
Background: High fasting plasma glucose (FPG) has been listed as one of the risk factors for bladder cancer. We here estimated the global, regional, and national levels of bladder cancer burden attributable to high FPG from 1990 to 2019.Methods: Bladder cancer data attributable to high FPG were extracted from the Global Burden of Disease Study 2019, and analyzed by age, sex, year, and location. Age‐standardized rates were utilized to evaluate the burden between different populations. The temporal trend of the burden was estimated through the Joinpoint analysis.Results: In 2019, high FPG contributed to 22,823.33 (95% uncertainty interval [UI], 4694.88–48,962.26) deaths and 399,654.91 (95% UI, 81,609.35–865,890.95) disability‐adjusted life years (DALYs) of bladder cancer globally. Since 1990, the global age‐standardized death and DALY rates of bladder cancer attributable to high FPG increased apparently by 39.18% and 41.48%, respectively. During the last 30 years, high FPG‐related age‐standardized death and DALY rates of bladder cancer have increased in all countries. In 2019, Central Europe showed the greatest high FPG‐related age‐standardized death and DALY rates of bladder cancer, but Andean Latin America had the lowest rates. Nationally, Lebanon showed the greatest high FPG‐related age‐standardized death and DALY rates of bladder cancer in 2019. High FPG‐attributable deaths and DALYs of bladder cancer were more considerable among males and older people. Countries with high SDI showed higher levels of age‐standardized death and DALY rates of bladder cancer due to high FPG and presented remarkable upward trends in rates in the last 30 years.Conclusions: Globally, the high FPG‐associated bladder cancer burden has remarkably increased in all countries, and showed a higher level among countries with higher SDI. Monitoring FPG levels among patients with bladder cancer is critical to lower the corresponding burden.Keywords
This publication has 43 references indexed in Scilit:
- Risk of bladder cancer in patients with diabetes mellitus: an updated meta-analysis of 36 observational studiesBMC Cancer, 2013
- Diverging sex-specific long-term effects of cigarette smoking on fasting insulin and glucose levels in non-diabetic peopleClinical Biochemistry, 2012
- National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2·7 million participantsThe Lancet, 2011
- Diabetes and risk of bladder cancer: a study using the National Health Insurance database in TaiwanDiabetologia, 2011
- Diabetes Mellitus, Fasting Glucose, and Risk of Cause-Specific DeathNew England Journal of Medicine, 2011
- Diabetes and risk of bladder cancerCancer, 2010
- Bladder Cancer Working Group ReportJapanese Journal of Clinical Oncology, 2010
- Diabetes, prediabetes and cancer mortalityDiabetologia, 2010
- New genetic loci implicated in fasting glucose homeostasis and their impact on type 2 diabetes riskNature Genetics, 2010
- Multiple socio-economic circumstances and healthy food habitsEuropean Journal of Clinical Nutrition, 2006